Tretiva is a synthetic retinoid medication primarily prescribed to treat severe acne. Its active ingredient isotretinoin works by modulating the activity of sebaceous glands and reducing inflammation. It decreases the size and output of oil-producing glands thereby limiting the conditions that lead to acne lesions. The drug also normalizes the process of skin cell turnover, preventing the formation of clogged pores. By influencing genetic pathways within skin cells, isotretinoin reduces the production of inflammatory mediators that cause redness and swelling. These combined effects lead to a long-lasting clearance of acne and a lower risk of new lesions developing. Overall the medication alters the skin's physiological response to hormonal signals and bacterial presence, resulting in the therapeutic outcome.

Tretiva is a medication classified as a retinoid used in dermatology. Its primary therapeutic role is to treat severe acne by modulating skin cell growth. Pharmacodynamically it binds to nuclear receptors that regulate keratinocyte differentiation. Pharmacokinetically it is absorbed through the skin and influences transcription pathways that reduce inflammation. The mechanism of action involves activation of retinoic acid receptors which alter gene expression to normalize follicular keratinization. This interaction ultimately decreases the size and activity of sebaceous glands and limits the proliferation of acne-causing bacteria.

Tretiva can cause dryness of the skin and lips. Some users report occasional nosebleeds. Sunlight sensitivity may lead to easier sunburn. Headaches are reported by a subset of patients. Elevated cholesterol levels can occur during treatment. Joint or muscle discomfort may be experienced. Mild gastrointestinal upset such as nausea is possible. Temporary hair thinning has been observed in rare cases.

Tretiva may cause dryness of the skin and lips as a frequent side effect. Some users experience mild nosebleeds due to nasal mucosal dryness. Dryness of the eyes can lead to irritation or a feeling of grittiness. Headaches are occasionally reported during the early weeks of treatment. A temporary increase in acne lesions may occur before improvement is observed. Sensitivity to sunlight can be heightened, making the skin more prone to sunburn. Elevated blood triglyceride levels are sometimes detected in laboratory tests. Mild gastrointestinal discomfort such as nausea may be experienced by some patients.